Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario
Current Oncology · 09.05.2025 · 32 (5) · 273
DOI: 10.3390/curroncol32050273 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Current Oncology, online erschienen am 09.05.2025. Verfasst von Soo Jin Seung und 4 weiteren Autor:innen. Beteiligte Einrichtung: HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada. Hauptthemen laut MEDLINE: Liposarcoma, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim Canada Ltd., Boehringer Ingelheim.
Abstract (Originalsprache)
Background
Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive tumour with poor survival outcomes in advanced settings. This study assessed the incidence/prevalence, treatment patterns, survival, healthcare resource utilization (HCRU), and costs for DDLPS patients in Ontario, Canada.
Methods
A retrospective cohort study was conducted among DDLPS patients between 2010 and 2022 using administrative databases. Overall survival, all-cause HCRU, and costs (2023 Canadian dollars, CAD) were compared based on advanced disease and resection status.
Results
The overall incidence and cumulative prevalence of DDLPS was 0.465 and 1.995 per 100,000 people, respectively. Of all 611 DDLPS cases (64.3% male, median age [IQR]: 67 [57–76] years), 40.3% and 61.0% had advanced and unresected disease, respectively. The median overall survival (mOS) was 69 months [IQR = 15–151] for the entire cohort, but this was significantly lower for advanced and unresected disease (p < 0.0001). Among patients receiving systemic treatments (N = 117), 81.2% were prescribed doxorubicin as first-line treatment. All-cause healthcare costs (2023 CAD) amounted to CAD 34,448 per person-year (PPY), with inpatient hospitalizations being the highest cost driver at CAD 14,522 PPY and 0.8 inpatient hospitalization PPY for all years. Advanced disease had higher HCRU and costs.
Conclusions
This is the first comprehensive real-world evidence study that quantifies the high mortality and cost burden associated with DDLPS in Canada.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
- Boehringer Ingelheim Canada Ltd., Burlington, ON L7L 5H4, Canada.
- Toronto Sarcoma Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
ORCID-Profile: Soo Jin Seung
Förderung
- Boehringer Ingelheim Canada Ltd.
- Boehringer Ingelheim
Zitieren
APA
Seung, S. J., Wong, A., Milan, R., Chandran, N., & Razak, A. R. A. (2025). Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario. Current Oncology, 32(5), 273. https://doi.org/10.3390/curroncol32050273
Vancouver
Seung SJ, Wong A, Milan R, Chandran N, Razak ARA. Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario. Current Oncology. 2025;32(5):273. doi:10.3390/curroncol32050273
BibTeX
@article{Seung2025,
author = {Seung, Soo Jin and Wong, Anisia and Milan, Raymond and Chandran, Nisha and Razak, Albiruni R Abdul},
title = {Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {5},
pages = {273},
doi = {10.3390/curroncol32050273}
}
EUVIMED